LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours

By LabMedica International staff writers
Posted on 12 Feb 2025
Image: The rapid diagnostic to detect neonatal sepsis can provide results within hours versus days (Photo courtesy of 123RF)
Image: The rapid diagnostic to detect neonatal sepsis can provide results within hours versus days (Photo courtesy of 123RF)

Neonatal sepsis is a life-threatening condition caused by bloodstream infections in newborns under 28 days old. Due to their underdeveloped immune systems, newborns are particularly vulnerable to infections. Each year, an estimated 2.5 million neonates or infants under one month of age die from sepsis, with the greatest impact in low- and middle-income countries. Since neonatal sepsis can progress quickly, it requires immediate intervention with IV fluids and antibiotics. For every hour treatment is delayed, the risk of death from neonatal sepsis increases by 7.6%. Researchers are now advancing a robust, cost-effective device that detects neonatal sepsis by utilizing advanced digital imaging and signal processing, delivering results within hours instead of days.

AstraDx (Beverly, MA, USA) is developing a technology that aims to detect pathogens, identify the specific pathogen, and perform phenotypic antimicrobial susceptibility testing (AST) directly from whole blood, producing results in just four hours. The company has been awarded a USD 3 million grant by the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X, Boston, MA, USA) to demonstrate the feasibility of its device for detecting neonatal sepsis. AstraDx’s innovative approach, which uses small blood samples and leverages advanced digital imaging and signal processing to identify pathogens and antimicrobial resistance in hours instead of days, could mark a significant advancement in neonatal sepsis diagnostics. This technology could revolutionize clinical decision-making, enabling rapid, targeted treatment for critically ill patients and contributing to the global fight against antimicrobial resistance.

“Our system for diagnosing bloodstream infections for even the worst pathogens is designed to be easy to use and affordable for populations worldwide, including underserved populations,” said Fran White, CEO of AstraDx. “We are committed to meeting the challenge of emerging, highly antibiotic-resistant superbugs. Rapid ID and AST specifically for neonates, addresses the need for better life-saving treatment for this especially vulnerable population.”

Related Links:
AstraDx 
CARB-X

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more